MannKind to Present at Upcoming Investor Conferences
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in four upcoming investor conferences in September 2025.
CEO Michael Castagna and CFO Chris Prentiss will present at the Wells Fargo Health Care Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 9). Live webcasts will be available on MannKind's investor relations website, with recordings accessible for 90 days post-event.
MannKind Corporation (Nasdaq: MNKD), sviluppatrice di prodotti terapeutici inalatori per malattie endocrine e polmonari rare, ha annunciato la propria partecipazione a quattro conferenze per investitori previste a settembre 2025.
Il CEO Michael Castagna e il CFO Chris Prentiss terranno presentazioni al Wells Fargo Health Care Conference (3 set), al Cantor Global Healthcare Conference (4 set), al H.C. Wainwright Global Investment Conference (9 set) e al Morgan Stanley Global Healthcare Conference (9 set). I webcast in diretta saranno disponibili sul sito per gli investitori di MannKind e le registrazioni potranno essere consultate per 90 giorni dopo ogni evento.
MannKind Corporation (Nasdaq: MNKD), desarrolladora de productos terapéuticos inhalados para enfermedades endocrinas y pulmonares raras, ha anunciado su participación en cuatro conferencias para inversores en septiembre de 2025.
El CEO Michael Castagna y el CFO Chris Prentiss presentarán en el Wells Fargo Health Care Conference (3 de sept.), el Cantor Global Healthcare Conference (4 de sept.), el H.C. Wainwright Global Investment Conference (9 de sept.) y el Morgan Stanley Global Healthcare Conference (9 de sept.). Los webcasts en directo estarán disponibles en la web de relaciones con inversores de MannKind y las grabaciones podrán verse durante 90 días tras cada evento.
MannKind Corporation (Nasdaq: MNKD)는 내분비 및 희귀 폐질환용 흡입 치료제 개발업체로, 2025년 9월에 열리는 네 건의 투자자 콘퍼런스에 참여한다고 발표했습니다.
CEO 마이클 카스탄나(Michael Castagna)와 CFO 크리스 프렌티스(Chris Prentiss)가 Wells Fargo Health Care Conference(9월 3일), Cantor Global Healthcare Conference(9월 4일), H.C. Wainwright Global Investment Conference(9월 9일), 그리고 Morgan Stanley Global Healthcare Conference(9월 9일)에서 발표합니다. 라이브 웹캐스트는 MannKind의 투자자 관계 웹사이트에서 제공되며, 녹화본은 행사 종료 후 90일간 시청할 수 있습니다.
MannKind Corporation (Nasdaq: MNKD), développeur de produits thérapeutiques inhalés pour les maladies endocrines et pulmonaires rares, a annoncé sa participation à quatre conférences investisseurs en septembre 2025.
Le PDG Michael Castagna et le CFO Chris Prentiss interviendront lors du Wells Fargo Health Care Conference (3 sept.), du Cantor Global Healthcare Conference (4 sept.), du H.C. Wainwright Global Investment Conference (9 sept.) et du Morgan Stanley Global Healthcare Conference (9 sept.). Des webcasts en direct seront disponibles sur le site relations investisseurs de MannKind, et les enregistrements pourront être consultés pendant 90 jours après chaque événement.
MannKind Corporation (Nasdaq: MNKD), ein Entwickler inhalativer Therapien für endokrine und seltene Lungenerkrankungen, hat seine Teilnahme an vier Investorenkonferenzen im September 2025 angekündigt.
CEO Michael Castagna und CFO Chris Prentiss werden beim Wells Fargo Health Care Conference (3. Sept.), Cantor Global Healthcare Conference (4. Sept.), H.C. Wainwright Global Investment Conference (9. Sept.) und Morgan Stanley Global Healthcare Conference (9. Sept.) präsentieren. Live-Webcasts sind auf der Investor-Relations-Website von MannKind verfügbar; Aufzeichnungen stehen 90 Tage nach den Veranstaltungen zur Verfügung.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:
Wells Fargo Health Care Conference (Boston)
Wednesday, September 3, 4:30 p.m. ET
Cantor Global Healthcare Conference (New York)
Thursday, September 4, 9:45 a.m. ET
H.C. Wainwright 27th Annual Global Investment Conference (New York)
Tuesday, September 9, 11:30 a.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference (New York)
Tuesday, September 9, 2:35 p.m. ET
Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind: Investor Relations Ana Kapor (818) 661-5000 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
When is MannKind (MNKD) presenting at the Wells Fargo Health Care Conference 2025?
How can investors access MannKind's (MNKD) September 2025 conference presentations?
Which executives will represent MannKind (MNKD) at the September 2025 investor conferences?
What is MannKind Corporation's (MNKD) main business focus?
